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A urinary calcium—citrate index for the evaluation of nephrolithiasis.
We have performed a multivariate analysis of urine abnormalities in
patients with calcium oxalate nephrolithiasis, in which effects of gender
were also considered. The characteristic of patients that most clearly
sets them apart from normal people is a high level of urine calcium for
any given level of urine citrate. Other urine measurements cannot
improve upon the separation between patients and normals provided by
urine calcium and citrate, and their abnormal relationship to each other.
Normal women have higher urine citrate and lower urine calcium than
normal men or patients of either sex; normal men differ from stone
forming men only moderately. Direct measurements of supersaturation
are not helpful in distinguishing between patients and normals, once
calcium and citrate have been considered. From our analysis, we have
derived a new index for evaluating the significance of urine calcium and
citrate levels that seems to offer a better basis for clinical diagnosis than
criteria presently in use.
This study concerns the evaluation of patients who form
calcium oxalate renal stones because of urinary abnormalities
due not to systemic diseases but to otherwise benign genetic
disorders, habits, and diet [1]. The abnormalities include high
urine excretion of calcium [1—10], oxalate [1, 3, 4, 5, 7, 81, and
uric acid [11], low levels of protective inhibitors [12—141 includ-
ing citrate 12, 3], and excessive urine supersaturation [15]. The
standard method of caring for this large group of patients, who
constitute the majority of calcium oxalate stone formers [1], is
to treat each abnormal urine chemistry as a separate disorder
using diet or medication [1, 16—181. In the present study, we
have used a multivariate comparison of urine chemistry values
in men and women with and without calcium oxalate stone
disease to identify the most impressive and uniform of these
abnormalities in stone formers, and have found the most
important one is an imbalance between calcium and citrate
levels.
Methods
Patients and normal subjects
Two hundred and thirty-five consecutive men and 95 women
with calcium oxalate nephrolithiasis were evaluated using our
usual laboratory protocol [1, 161 that also included urine citrate
and calcium oxalate supersaturation measurements [15]. Their
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stone disease was not due to any systemic cause such as
primary hyperparathyroidism, enteric hyperoxaluria, renal tu-
bular acidosis, sarcoidosis, immobilization, or Paget's disease,
nor to drugs such as acetazolamide, vitamin D supplements,
glucocorticoid hormones, antacids, or calcium supplements [1,
161. As expected, their conventional pathogenetic classifica-
tions were mainly idiopathic hypercalciuria [16], hyper-
uricosuria [11], dietary oxaluria [1], a combination of these, or
no metabolic disorder. Thirty—three normal men and 27 normal
women were chosen for an age range (20 to 55) comparable to
the patients, and an absence of any known medical disorder.
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Laboratory evaluation
Three 24 hr urines were collected from outpatients eating
their usual diet and following their normal habits. A blood
sample was drawn, without stasis, between 8 and 9 am. at the
conclusion of each urine collection. Calcium, phosphorus,
magnesium, creatinine, uric acid, sodium, and potassium levels
were measured in blood and urine; oxalate, citrate, pH, and
supersaturation were measured in urine only. One to three
collections were obtained for each normal subject. Thymol was
the urine preservative.
Calcium and magnesium were measured by atomic absorp-
tion spectrophotometry, uric acid by the unease method, phos-
phorus and creatinine by autoanalyser, sodium and potassium
by flame photometry, urine oxalate by the zinc reduction
method, citrate by the citrate lyase method [191, and supersat-
uration using the concentration product ratio [15]. In the latter,
calcium and oxalate levels were measured in the urine before
and after incubation with 10 mg/mI of calcium oxalate
monohydrate crystals, at 37°C, for 48 hr—an interval long
enough to permit the crystals and the urine to come into
equilibrium so that urine calcium and oxalate levels no longer
change. The ratio of the calcium oxalate product before to that
after incubation, the concentration product ratio (CPR), is a
measure of supersaturation. Values above 1 indicate super-
saturation in multiples of the solubility limit, values of 1 indicate
no net crystal growth, values below 1 indicate undersat-
uration—dissolution of the preformed crystals.
Calculations
Urine values were measured as concentrations, with the
exception of the CPR. We also expressed each as a 24 h
excretion rate, and as excretion per g of urine creatinine, k of
body wt, or liter of creatinine clearance. Creatinine clearance
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Table 1. Selected urinary measurements
Measurement
Women Men
Patient Normal Patient Normal
Volume, ml/24 hr 1370 72 1372 136 1626 4Ø( 1293 84
Weight, kg 66 2 62 2 81 1 77 2
Creatinine, mg/24 hr 1194 24 1250 40 1886 22 1876 69
Creat. Cl., liter/24 hr 157 4 152 5 191 3 182 6
Calcium, mg/24 hr 206 9C 125 12 254 7C 181 14
Calcium, mg/liter 171 8C 105 11 168 4 157 14'
Oxalate,mg/24hr 29± 25±1 39±1" 33±2
Oxalate, mg/liter 23 1 22 2 25 .4 28 l
Citrate, mg/24 hr 551 24b 729 47 516 IS 547 31
Citrate, mg/liter 463 24" 652 71 349 I 1" 473 37C
Uric Acid, mg124 hr 557 13 520 21 740 11 699 33
Uric Acid, mg/liter 472 18 484 50 502 I" 597 37i
Un. Uric Acid, mg/liter 101 8 113 23 99 5 122 18
pH 6.01 .04 5.98 .08 6.08 .02 6.11 .08
CPR 1.64 03" 1.44 .06 1.70 .02 1.66
Sodium, mEq/24 hr 138 5C 109 5 189 4 169 9
Potassium,mEq/24hr 47±1 51±3 62±1 60±3
Magnesium, mg/24hr
Phosphorus, mg/24 hr
84 3
773 18
84 5
698 32
111 2
1055 17b
99 6
889 48
a differs from normal, same sex, P < 0.05
differs from normal, same sex, P < 0.02.
C differs from normal, same sex, P < 0.001.
d differs from women, same group, P < 0.02.
differs from women, same group, P < 0.001.
All values are mean SEM. Excretion rates of calcium, oxalate, uric acid, sodium, magnesium, and phosphorus by men exceed those of
corresponding women, P < 0.01 for all comparisons. Urine calcium and citrate excretion of women and men patients exceeded normal (P < 0.01)
when expressed per kg body wt, g creatinine, or liter of creatinine clearance (not shown).
was calculated as the ratio of 24 h creatinine excretion to the
serum creatinine. Apart from serum creatinine, blood measure-
ments were used here only to guide us in excluding patients
with hypercalcemia, and are not analyzed further. The mean
value of each urine measurement was calculated for each
person, and mean values were taken for subsequent analyses,
so each patient and normal contributed only one set of values.
The assembledge of mean values was analyzed using stan-
dard methods for digital computer [201. Simple t-tests, and
analysis of variance were used to evaluate individual differ-
ences between normals and patients. Stepwise discriminant
analysis was performed between patients and normals of the
same gender. Stepwise partial regression was used to determine
predictors of supersaturation in urine of normals and patients.
Analysis of covariance was used to ascertain the dependence of
calcium excretion upon sodium excretion rate.
Table 2. Discriminant analysis of urine ch
and patients
emistry values in normals
Measurement
Women Men
0 1 2 3 0 1 2 3
Calcium
Citrate
CPR
Oxalate
U. uric acid
pH
Uric acid
Volume
15.3
10.2
9.9
1.2
0.45
0.16
0.08
0
X X X
30.6 X X
3.2 6.03 X
0.26 1.54 0.06
3.4 0.05 0.37
0.66 0.29 0.42
9.78 0.41 1.76
4.23 0.02 0.13
0.71 4.43 X
13.7 X X
0.27 0.82 0.16
3.97 0.34 1.31
2.15 0.26 0.92
0.16 0.49 0.14
8.36 1.65 5.75
8.81 1.62 4.95
X
X
0.62
0.002
0.12
1.04
X
1.01
All values are F statistics. X indicates the variable was used in the
discriminant. Numbers above columns indicate the step of the discrimi-
nation; at 0, no variable has been chosen; at subsequent steps, the
indicated variables have their values set to the grand mean for both
groups, and all F values are recalculated.
Results Discriminant analysis
Individual differences
Compared to normal, women patients were heavier, their
urine contained more calcium, oxalate, sodium, phosphorous
and uric acid and less citrate, and was more supersaturated
(Table 1). Unlike women, men patients had abnormally high
urine volumes (Table 1). Consequently, calcium and oxalate
concentrations were not elevated despite hypercalciuria and
hyperoxaluria, and uric acid and citrate concentrations were
lower than normal despite comparable excretion rates.
Stepwise discriminant analysis (Table 2) identified calcium
and citrate concentrations (both sexes), CPR (women), and uric
acid concentration (men) as independent abnormalities. At each
step, one variable is set to the grand mean of the normal and
patient groups combined, and the value of each remaining
measurement recalculated for each subject to a new value,
using its covariance with the removed variable and the reset
value of the removed variable.
Discriminant functions using calcium and citrate distin-
guished patients from normals very well (Table 3), especially
among women. Removal of CPR made almost no difference in
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Table 3. Correct classification of patients and normals by
discriminant functions employing different normalization techniques
Women Men
Measurement P N B P N B
(95) (27) (122) (235) (33)
Concentrations 78(80) 85(81) 80(80) 69 58
mg/24 hr 77(81) 85(81) 79(81) 56 70
mg/kg body wt 80(82) 81(81) 80(82) 64 70
mg/g Creatinine 77(82) 88(85) 80(83) 63 79
mg/liter Creat clearance 77(80) 81(81) 78(80) 62 72
All' 79(82) 89(85) 81(83) 66 75
(268)
67
57
65
65
63
67
women, and CPR was not used in men. Analyses using excre-
tion rates divided by wt, urine creatinine, and creatinine clear-
ance, were slightly more successful (Table 3) for both sexes.
Inclusion of all primary and calculated data led to selection of
calcium excretion per g creatinine in both sexes, and citrate
excretion per liter of creatinine clearance in women and citrate
concentration in men. We chose the discriminant without CPR,
and based only on concentrations, as probably best for clinical
use in women, as CPR is not widely available, and calculations
based on body wt or creatinine excretion or clearance add only
marginally to correct selection but considerably to the effort of
practical use (Table 3). For men, calcium/g creatinine improved
accuracy, and was chosen.
Actual values of urine calcium and citrate from normals and
patients create clinical nomograms (Figures 1 and 2) to whose
regions urine from stone formers can be compared. The lines of
the discriminant functions divide the graphs into normal (upper
left) and patient (lower right) zones that are defined not only by
actual calcium and citrate levels but by the balance between
them; compared to normals, patients of either sex have a lower
level of citrate at any particular calcium level. The upward
slopes of the discriminant lines, as well as the data themselves
make it clear that calcium-citrate balance is more abnormal in
patients than are the actual levels of either calcium or citrate,
which both overlap normal values extensively.
The discriminant scores derived from citrate and calcium
(Fig. 3) are a quantitative diagnostic index, Individual values of
the patient scores overlap normal values less than any individ-
ual measurements. The score of zero gives the best overall
separation of patients from normals, but clinicians may wish to
use scores that are more sensitive or more selective, depending
upon their goals. Equations for scores in women (Sw) and men
(Sm) respectively are: Sw = 0.02053Ca — 0.00548Cit + 0.224;
Sm = 0.0l489Ca -- 0.00336Cit — 0.3491; Cit is urine citrate,
mg/liter; Ca is urine calcium, mg/liter in women and mg/g
creatinine in men.
It may be that the higher urine volume we observed in our
men with stones is not intrinsic to them, but simply results from
local treatment practices that somehow influence men, but not
women, to drink more water. If so, the discriminant equation
based only on urine concentrations of calcium and citrate may
be best for men, as it is for women, in clinical settings where the
higher urine volume of men patients does not regularly influ-
Urine calcium, mg/liter
Fig. 1. Urine calcium and citrate concentrations in women with (•) and
without (0) calcium oxalate nephrolithiasis. The line represents the
discriminant equation: citrate = 3.746 calcium + 41.1, that gives the
best identification of patients and normals (Table 3).
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ence results. The equation of score, Sm, in men, based on urine
concentrations is: Sm = 0.00624Ca — 0.OO46lCit + 0.87922.
Predictors of urine supersaturation
CPR added little to the discrimination of patients from
normals, because it correlated well with other urine measure-
ments (Table 4). Urine oxalate levels were the most important
of these and did not differ between patients and normals by very
much (Tables 1 and 2). The only differing urine value that also
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aCa Used calcium in mg/creat (both sexes), and citrate/creatinine clear-
ance (women) and mg/liter (men); all others used calcium and citrate
excretion, directly or normalized as shown. Values are percentages of
subjects classified correctly; numbers in parenthesis are when CPR was
also available to the program, and was used.
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Fig. 2. Urine calcium/g crearinine and citrate concentrations in men
with (S) and without (0) calcium oxalate nephrolithiasis. The line
represents the discriminant equation: citrate 4.432 calcium — 103.9,
that gives the best identification of patients and normals (Table 3).
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Women Men
P N P N
Oxalate 0.72 Oxalate 0.63 Oxalate 0.56 Oxalate 0.54
Calcium 0.79
—
Uric Acid 0.65
Calcium 0.68
Calciuma 0.60 Oxalat&' 0.65
was correlated with CPR was calcium concentration (in
women), which was used in the discriminant score.
Effects of treatment on calcium—citrate score
One way to assess the clinical value of the score based upon
calcium and citrate is to measure the score during treatment
designed to prevent calcium stone recurrence. We have dis-
cussed such treatment, mainly of hypercalciuria and hyper-
uricosuria, elsewhere [1, 11, 15—17, 36]. In our patients, we
have followup data during treatment of 47 women and 114 men
that include measurement of urine citrate, and which were
obtained during a period in which each patient was entirely free
of new stone formation, as judged by the clinical and radio-
graphic criteria we normally employ [11. Compared to the
pretreatment results, scores fell in both sexes (Table 5). How-
ever, even though all of the patients were free of new stones,
scores were still above those of corresponding normal subjects.
In other words, treatment reduced the urine calcium citrate
imbalance, but did not fully restore it to normal.
Relationship between sodium and calcium excretion
Because sodium excretion was higher in women patients than
normals, and calcium excretion in hypercalciuria is said to
reflect a high sodium excretion [21], the relative hypercalciuria
of women patients could in part reflect a higher sodium intake.
However, the difference in calcium excretion persisted when
Sex Pretreatment Treatment Normals
Women 1.20 0.15 0.38 O.2 —1.02 0.3'
Men 0.48 0.06 0.17 0.OT —0.45 015a.b
the effects of higher sodium excretion were allowed for by
analysis of covariance. Sodium and calcium excretions were
well correlated: regression coefficient = 0.661 0.157 (sEM)
= 4.20, P < 0.001. The slopes of the regressions within the
two groups were not different (F = 0.479), the slopes differed
significantly from zero in both groups (P < 0.0001), and the
means for calcium excretion adjusted for the difference in
sodium excretion differed markedly: 202 8 vs. 139 15,
patients vs. normals, P = .0003. In other words, hypercalciuria
could not be accounted for by natriuresis. In men, sodium and
calcium excretions also were well correlated: regression coef-
ficient = 0.752 0.103, t = 7.28, P < 0.001. The slopes of the
regressions within the two groups were not different (F =
0.984), the slopes differed significantly from zero in both groups
(P < 0.0001), and the means for calcium excretion adjusted for
the means in sodium excretion differed: 252 6 vs. 194 16,
patients vs. normals, P = 0.001.
Comparison between women and men
Because normal men produce no more urine than women
(Table 1) yet excrete more calcium, oxalate, and uric acid, their
urine is more concentrated with all three materials, and CPR is
higher. Men with stones have higher urine volumes than
women, so their high excretion rates do not express themselves
in higher concentrations.
The most dramatic differences between genders are best
visualized by plotting mean values of urine calcium and citrate
concentrations (Figure 4). Normal women stand out as remark-
able for their low calcium and high citrate. Normal men and
stone forming women resemble one another, whereas men with
stones have only slightly higher calcium concentrations, and
moderately lower citrate. Put another way, normal men are like
women with stones.
Discussion
Urine calcium and citrate are the two measurements that best
distinguish stone formers from normal. Urine volume in men,
body wt, uric acid excretion and CPR in women, and oxalate
and sodium excretion in either sex are abnormal in stone
formers, but are so correlated with calcium and citrate that each
adds no independent information with respect to classifying a
urine as belonging to a stone former or a normal. If it is true that
abnormalities that cause stones are most consistently found
among stone formers, then urine calcium and citrate abnormal-
ities appear to play strong and independent roles in producing
calcium oxalate stones.
The role of calcium is well known. Over one—half of men and
two—thirds of women [18] have normocalcemic idiopathic
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Table 5. Effects of treatment upon calcium citrate discriminant
scores in 47 women and 114 men with calcium oxalate nephrolithiasis
—1
6
18
3038475566
89
96
98
99
—8
normals! patients
Women
a vs. pretreatment, P < 0.001; h vs. treatment, P < 0.001; Mean
values SEM for pretreatment and normals are for the data detailed in
Figure 3; scores were calculated using urine citrate concentration, both
sexes, urine calcium concentration in women, and urine calcium per g
urine creatinine in men.
3 I
normals patients
Men
Fig. 3. Discriminant scores for women and men with (S) and without
(0) calcium oxalate nephrolithiasis. Scores calculated from discrimin-
ant equations in text. U = 5 cases, rest 1 case each. Mean values of
scores in Table 5.
Table 4. Prediction of CPR from urine chemistry values
Values are correlation coefficients; chemistry values are concentra-
tions in mg/liter except for amg/24 hr. Successive entries in each column
show the stepwise addition of measurements to the predictive regres-
sion equation, and the resulting increase in the correlation coefficients.
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Fig. 4. Urine citrate versus calcium concentration (tsrsyl in women
(open symbols) and men (closed sytnhols) with (square) and without
(circles) calciu,'n oxalate nephrolithiasis. Values detailed in Table I.
hypercalciuria, a familial [22] and probably hereditary [231 trait.
Hypercalciuria increases urine supersaturation l5], and high
supersaturation promotes crystal formation and growth. Reduc-
ing urine calcium with diuretics reduces supersaturation [151
and new stone formation [1, 16].
The role of citrate is less well established. Citrate could be an
important natural inhibitor of stone formation, because it slows
the growth of calcium oxalate monohydrate crystals at the
millimolar concentrations found in urine [24]. Citrate associates
with calcium to form a salt that is more soluble than calcium
oxalate, and can therefore reduce calcium oxalate supersatura-
tion—by reducing urine free calcium ion concentration—with-
out causing calcium citrate crystallization [251. Calculations
based upon simultaneous consideration of multiple ion associ-
ations in a normal urine place calcium citrate at about 45% of
the total urine calcium that is non-ionic [25]; since 50% of urine
calcium is bound, and therefore non-ionic, low urine citrate
could easily increase ionic calcium and, therefore, supersatu-
ration. The fact that it is relatively low in urine of women and
men patients supports a role for citrate as a normal protection
against stone disease.
That the balance between calcium and citrate is more abnor-
mal in urine of stone formers than urine levels of either
substance alone probably reflects the importance of both cal-
cium binding and direct effects of citrate upon crystal nucle-
ation and growth. It may not be so much the absolute urine
calcium or citrate levels that determine risk of stone as the
relative excess of calcium over citrate. This seems to he the
implication of our data, and accords with what is known about
the interactions of citrate with calcium and calcium oxalate
crystals.
A similar relationship has been described between calcium
oxalate supersaturation and total urine calcium oxalate crystal
growth inhibition [26]; patients had not only abnormally high
urine supersaturation, hut a low ratio of inhibition to supersat-
uration. The nature of the molecules that cause urine crystal
growth inhibition is still uncertain; most of the effect is due to
molecules larger than citrate, including glycosaminoglycans
[27] and a glycoprotein of unusual properties [28]. The impor-
tant result of this study is that citrate not only provides a
context for interpreting the clinical significance of urine calcium
levels but is also a well defined molecule whose level in urine
can be measured precisely and raised by medical treatment [29].
Gender greatly affects urine chemistry. Normal women seem
very different from normal men and from patients of either sex,
in having low urine calcium and high citrate. Normal men
produce urine like that of stone forming women, and only
marginally lower in calcium and higher in citrate than stone
forming men, Put otherwise, normal men appear closer to stone
forming patients than to normal women, and could be at an
intrinsically higher risk for stones. In fact, about 80% of calcium
oxalate stones occur in men [18], though men and women are
about equal in the population. The urine values of normal
women may be the correct "gold standard" for normal, if by
normal we mean a low probability of stone. Our findings may
partly explain the relative scarcity of calcium oxalate stones in
women.
Another striking gender difference is that uric acid excretion
of men with and without stones and urine uric acid concentra-
tion of normal men exceed that of women (Table 1). Because its
volume is high, urine of men with stones does not have a high
uric acid concentration. In a subset of patients, mainly men
[11], who have urine flow rates that do not exceed normal [11,
30] and elevated urine uric acid excretion rates, urine is more
supersaturated with respect to undissociated uric acid than
among normal men, and uric acid crystallization is more likely
to occur. There is good evidence that uric acid crystals can
promote calcium oxalate crystallization [31] and that lowering
urine uric acid levels can reduce calcium stone formation in
patients with excessive urine uric acid supersaturation [32]. The
lack of any detectable independent abnormality of urine uric
acid in this study suggests it is a feature of only a fraction of
patients, compared to calcium and citrate that seem generally
abnormal. However, the uric acid difference between men and
women may be another reason why men are more prone to
calcium stone disease.
Urine oxalate presents a similar picture. Men excrete more
oxalate than women, and have higher concentrations of it that
may contribute to their greater propensity to stones.. But the
differences in calcium and citrate between patients and normals
of the same sex so overshadow those of oxalate that oxalate
contributes little to differentiating patients from normal, and
does not enter our discriminant equations. Nevertheless, in
some patients elevated urine oxalate levels may well play a
major role in the genesis of stones.
We have tested our calcium citrate discriminant equation
during treatment of our patients, mainly with thiazide diuretic
agents, allopurinol, and altered diet and fluid intake [I, II,
15—17, 32]; the score falls towards, but does not reach normal
values. Other tests could include an attempt to correlate activ-
ity of stone disease with score, but our population is not ideal
for that purpose. All of the patients formed recurrent stones
before entering our program, and the mean interval between
their last new stone and entering the program was about one
year, as we have described elsewhere [17]. Another test would
be a prospective evaluation of prople who have never formed a
100 120 140 160 180
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stone, comparing score to eventual stone occurrence; our data
do not include such follow-up of our normal subjects.
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